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Introduction
Proximal autosomal recessive Spinal Muscular Atrophy (SMA) is a devastating childhood form of motor neuron disease, targeting lower motor neurons in the ventral horn of the spinal cord resulting in denervation and atrophy of muscles in the limbs and trunk [1] . It is the most common genetic cause of infant mortality in the human population, with an incidence of around 1:6,000-10,000 [1] [2] [3] , and is caused by low levels of the survival motor neuron protein (Smn). Smn is the ubiquitously-expressed protein product of a gene which exists in two near identical copies: SMN1 and SMN2 [3, 4] . Reduced protein levels result from loss or disruption of the telomeric SMN gene (SMN1) but retention of the centromeric SMN gene (SMN2). The disease is characterised by an early disruption of neuromuscular connectivity, in the form of functional disruption and structural loss of neuromuscular junctions, which precedes a loss of lower motor neuron soma from the spinal cord and wasting of skeletal muscle [5] [6] [7] [8] [9] . Despite a clear understanding of the genetic cause of SMA, our understanding of the cellular and molecular mechanisms through which mutations in SMN lead to selective motor neuron loss and resultant clinical symptoms remains incomplete [1] .
Several studies have suggested that reduced Smn protein levels can have a significant influence on neurodevelopmental processes in lower motor neurons. For example, results from experiments using cultured neurospheres have shown that neuronal differentiation is inhibited in Smn-/-;SMN2 cells [10] and in vitro experiments utilising Smn-/-;SMN2 motor neurons reported reduced axon outgrowth [11, 12] . Furthermore, axon outgrowth and pathfinding have been shown to be compromised in zebrafish and Xenopus models of SMA [13, 14] . Although a failure to establish the neuromuscular system during embryogenesis appears unlikely to contribute to any developmental phenotype [15] , these studies suggest that deficiencies in motor unit development (controlling factors such as motor unit branching, size, pruning and function) may play a major role in conferring pre-symptomatic vulnerability upon lower motor neurons. Indeed, these studies have led to the suggestion that SMA may be caused by incorrect development of the neuromuscular system, which would subsequently confer an intrinsic vulnerability upon lower motor neurons presymptomatically, during pre-natal stages of growth and maturation. If this model of SMA pathogenesis turns out to be correct, then attempts to rescue the neuromuscular system postnatally (e.g. by elevating levels of Smn protein using gene therapy or pharmaceutical approaches [16, 17] ) would likely have significant limitations. However, if pre-symptomatic developmental abnormalities are not a major feature of SMA, the neuromuscular system may remain intact until the postnatal onset of symptoms and therefore be more amenable to rescue.
If prenatal developmental processes such as neuronal outgrowth and axon branching significantly contribute to SMA pathogenesis in mammals in vivo, we would expect to observe significant changes in the gross and/or fine morphology of neuromuscular connectivity, and/or changes in gene expression patterns in the spinal cord, preceding the onset of neuromuscular pathology in an established mouse model of severe SMA (Smn-/-;SMN2 [18] ). To directly test this, we have undertaken a combined high-resolution analysis of neuromuscular morphology and gene expression in SMA mice at a pre-symptomatic age (postnatal day 1; P1). We have taken advantage of previous observations that different muscles/muscle regions are differentially vulnerable to pre-synaptic pathology [7] and examined pre-symptomatic development in neighbouring populations of lower motor neurons and neuromuscular junctions that are known to be subsequently vulnerable or resistant to pathological changes at later stages of disease progression (P5). We show that morphological perturbations in pre-symptomatic developmental pathways are neither present nor necessary 5 for subsequent lower motor neuron pathology to occur in SMA in vivo. Parallel gene expression analyses of pre-symptomatic spinal cord from Smn-/-;SMN2 and slightly less severe Smn-/-;SMN2;delta7 [19] mice confirmed the absence of any disruption of developmental pathways, whereas equivalent microarray analyses at late-symptomatic ages indicated an extensive breakdown in neuronal integrity, implicating extracellular matrix stability, myelination and growth factor signalling pathways in disease pathogenesis.
Results

No detectable morphological abnormalities in pre-symptomatic development in either vulnerable or non-vulnerable motor units in severe SMA mice.
To establish whether pre-symptomatic developmental abnormalities are a significant feature of SMA pathogenesis in vivo we initially examined morphological correlates of lower motor neuron connectivity in the Smn-/-;SMN2 mouse model of severe SMA at pre-symptomatic ages (post-natal day 1; P1 [18, 7] ). We have previously shown that, in our hands, Smn-/-;SMN2 mice (as well as less severe Smn-/-;SMN2;delta7 mice; see below) are indistinguishable from their wild-type littermates at P1 and that pathological changes in the neuromuscular system are almost entirely absent [7; Baumer et al., manuscript under review].
The homogeneously fast-twitch Levator Auris Longus (LAL) muscle provided us with an excellent model system with which to study selectively vulnerable populations of lower motor neurons in these mice, allowing a direct comparison of neighbouring populations of differentially-affected motor units whilst eliminating variables such as nerve stump length, muscle fibre type and muscle function [7] . Whole mount LAL muscles from P1 Smn-/-;SMN2 and litter-mate control mice (Smn+/+;SMN2,) were labelled with antibodies against 150kDa neurofilament to reveal axonal and synaptic morphology and rhodamine-conjugated α-bungarotoxin to label post-synaptic acetylcholine receptors at the neuromuscular junction [7, 20] .
Confocal micrograph montages of the whole LAL muscle (incorporating both caudal and rostral bands) allowed analysis of the gross muscle innervation pattern in pre-symptomatic P1 mice ( Figure 1 ). No differences were observed between the gross innervation patterns of either the rostral (non-vulnerable motor units) or caudal (vulnerable motor units) bands of the LAL in Smn-/-;SMN2 and litter-mate control mice (N=8 control muscles; N=14 Smn-/-;SMN2 muscles). Endplates were clustered into distinct and highly characteristic innervation bands in all muscles examined: termed C1 and C2 in the caudal band and R1-5 in the rostral band ( Figure 1A ). Axons entered adjacent to region C1 in all muscles examined and, although there was a small amount of normal biological variability within genotypes, gross intra-muscular nerve branching patterns were not altered in Smn-/-;SMN2 muscles ( Figure   1D ). Quantification of the numbers of neuromuscular synapses in regions C2 and R3-5 (selected because these areas were least likely to suffer damage during muscle dissection) revealed no differences between Smn-/-;SMN2 and control mice ( Figure 1E,F) . This was in agreement with previous studies that reported no obvious discrepancy in the initial embryonic establishment of neuromuscular innervation patterns in SMA mice [15] .
Next, we considered the possibility that pre-symptomatic changes in lower motor neuron branching and motor unit size could conceivably lead to excessive demands being placed on individual lower motor neurons (e.g. functionally and/or energetically), thereby damaging the cell and pre-disposing it to subsequent degeneration. Such defects in axonal pathfinding and/or branching would most likely manifest as alterations in the number of axons present in intramuscular nerve bundles. We therefore quantified axon number in intramuscular nerve 7 bundles innervating regions C2 and R3 (two anatomically highly-consistent areas of the LAL muscle) in Smn-/-;SMN2 and control mice (Figure 2 ). Axons were only quantified in areas of the muscle where the complete endplate band could be seen in order to ensure that no other axon branches were entering the endplate band from a different nerve bundle. We did not observe sensory axons in any of the intramuscular axon bundles investigated (i.e. there were no axon profiles extending beyond the endplate band innervating sensory organs), meaning that all analyses only contained motor axons innervating the endplate region under investigation. Initial attempts to quantify the numbers of individual axons in intramuscular nerve bundles by undertaking analyses on raw confocal stacks and z-projections proved inconsistent and unreliable ( Figure 2A&C ). To achieve the necessary resolution required for accurate and robust analysis, confocal stacks were subjected to deconvolution analyses ( Figure 2B&D ). Quantification of axon numbers normalised to the number of endplates innervated revealed no difference in the numbers of axons innervating either C2 or R3/4 regions of Smn-/-;SMN2 or control mice ( Figure 2E ).
We next considered the possibility that subtle differences in the terminal branching of lower motor neurons (at the level of axonal inputs to individual neuromuscular junctions) could lead to hyper-innervation of muscle and a corresponding increase in motor unit size presymptomatically in SMA. To address this possibility we counted the number of axon collaterals converging on individual post-synaptic endplates at neuromuscular junctions in both bands of the LAL muscle from Smn-/-;SMN2 and control mice. Note that at this age, neuromuscular junctions are normally poly-neuronally innervated, as the process of developmental synapse elimination is ongoing. No significant differences were found in the average number of inputs converging on endplates in either rostral or caudal bands between genotypes ( Figure 3 ). There was a small, but noticeable, trend towards an increased number of inputs in Smn-/-;SMN2 mice compared to controls. However, as this small increase was present in both bands of the LAL, and equivalent levels were also observed in heterozygote controls (data not shown), these small differences are unlikely to contribute to subsequent selective neuromuscular vulnerability in the caudal band of the LAL.
During our analyses of P1 muscles we observed numerous axon sprouts, in the form of neuronal projections extending from pre-synaptic motor nerve terminals (Figure 4) , that have not been previously reported in the literature. These 'developmental sprouts' were consistently present in all bands of all muscles analysed, including both Smn-/-;SMN2 and litter-mate control mice. Developmental sprouts ranged in size from under 5µm to around 250µm. To confirm that this was a natural phenomenon, and that it was not occurring due to the presence of the SMN2 transgene, we examined P1 muscles from wild-type CD1 mice (a completely unrelated genetic strain). Terminal developmental sprouts were present in CD1 mice and were indistinguishable from those observed in Smn-/-;SMN2 and control mice at the same age (Supplementary Figure 1) . Whilst this finding clearly warrants further investigation in future studies of normal neuromuscular development, it also serves to demonstrate that the 'developmental sprouts' described here are not pathological and are distinct to previously described 'denervation-induced sprouts' which occur as a compensatory response to a loss of synaptic innervation at the neuromuscular junction [21] . However, neither the numbers of small (<150µm; see methods) nor larger 'super sprouts' (those >150µm in length) were modified in pre-symptomatic Smn-/-;SMN2 mice ( Figure 4 ).
Taken together, these data show that pre-symptomatic development of lower motor neuron connectivity, as far as can be observed using morphological techniques, occurs normally in both vulnerable and non-vulnerable motor units in severe SMA mice. Figure 5B ). However, we observed an increase in endplate maturation in the caudal band of the LAL in mice from both genotypes, as evidenced by an increase in the number of folded and perforated endplates. This finding is consistent with motor units in the caudal band conforming to fast-synapsing 'FaSyn' characteristics, being developmentally more advanced than their delayed-synapsing 'DeSyn' neighbours [7, 24] (note that FaSyn and DeSyn characteristics of motor units have no relevance to the fast-twitch / slow-twitch phenotype of motor units).
No detectable differences in pre-symptomatic development between differentially vulnerable fast-twitch and slow-twitch muscles
Our finding that there were no detectable abnormalities in the development of lower motor neuron connectivity in both the rostral and caudal bands of the LAL implied that abnormal pre-symptomatic neuromuscular development does not contribute to the increased vulnerability of motor units in the caudal band of the LAL [7] . However, these analyses compared two bands of a homogenous fast-twitch muscle (albeit with different FaSyn/DeSyn characteristics). It therefore remained possible that abnormalities in pre-symptomatic development of lower motor neuron connectivity may contribute to the increased vulnerability of lower motor neurons innervating slow-twitch muscles compared to those innervating fast-twitch muscles [7] . To investigate this possibility, we increased the scope of our experiments to examine two muscles immediately deep to the LAL muscle: abductor auris longus (AAL) and auricularis superior (AS). The AAL is a predominantly fast-twitch muscle whilst the AS is predominantly slow-twitch ( Figure 6 ). We chose these muscles for comparison because of their close proximity and function to one another (and the LAL) as well as their common innervation by the facial nerve (eliminating variables such as nerve stump length and body position, while still allowing whole mount analysis of the complete innervation pattern within a muscle). In late-symptomatic (P5) Smn-/-;SMN2 mice, there was approximately 25% denervation in the slow-twitch AS muscle while the fast-twitch AAL remained relatively unaffected ( Figure 6 ). The increased vulnerability of slow-twitch muscles at late-symptomatic stages was therefore reflected in the increased pathology observed in the AS muscle.
Comparable analyses of pre-symptomatic development to those detailed above for the LAL muscle revealed no significant differences in gross or fine neuromuscular development in the AAL or AS muscles between Smn-/-;SMN2 and control mice ( Figure 7 ). Interestingly, more advanced endplate maturation was observed in the less vulnerable AAL muscle compared to the AS muscle.
Minimal changes in pre-symptomatic gene expression in mouse models of SMA.
The experiments detailed in this study strongly suggest that lower motor neuron connectivity Table 1 ). The largest change observed was in expression levels of SMN1, providing an internal control for the sensitivity of the experiment. The other two genes identified fell close to the margin of the 1.5 fold cut off (1.6 fold down regulation and 1.7 fold up-regulation; Table 1 ), but neither are considered important for development of the neuromuscular system.
To validate the virtual absence of gene expression changes in the Smn-/-;SMN2 microarray data, we repeated the microarray experiment using pre-symptomatic (P1) spinal cord tissue from the less severely affected Smn-/-;SMN2;delta7 mouse model of SMA (N=4 mice per genotype, littermate matched; [19] ). These experiments revealed a similar lack of large-scale expression changes for genes implicated in developmental pathways (Table 2) . Taken together, these data suggest that reduced SMN expression levels exert no significant effect on pre-symptomatic gene expression in the spinal cord in vivo.
Significant changes in gene expression were present in late-symptomatic Smn-/-;SMN2 mice
As our morphological and gene expression analyses of SMA mice demonstrated that modifications in pre-symptomatic developmental pathways are unlikely to impact on subsequent SMA pathogenesis, we concluded that the breakdown of lower motor neurons is more likely due to the instigation of post-natal degenerative pathways. In order to gain insight into the identity of cellular and molecular pathways underlying breakdown of the neuromuscular system in SMA, we repeated our microarray expression analysis using latesymptomatic (P5) spinal cord from Smn-/-;SMN2 mice (N=3 mice per genotype, littermate matched). Of the 16,755 individual genes investigated, 160 were significantly changed (P<0.05, unpaired t test) greater than 1.5 fold (Table 3 shows changes >2 fold;
Supplementary Table 1 shows changes >1.5-1.99 fold). No multiple testing correction was applied to the data (e.g. Benjamini and Hochberg) as it was considered to be over-stringent for microarray data of this nature and sample size (i.e. no genes would be expected to pass the test). Array data were therefore validated at the protein level using quantitative western blotting (see below). Both increases and decreases in gene expression levels were observed in Smn-/-;SMN2 mice, but none of the significantly increased genes were changed greater than 2-fold (therefore genes with increased expression can only to be found in Supplementary Table 1 ). The biggest single change was found for a gene in the myelination pathway, where we detected a significant 6.5 fold decrease in expression of myelin protein zero (P0). These results were in stark contrast to the P1 results (a 53 fold increase in the number of changed genes), underlining the minimal changes seen pre-symptomatically. A comparison of P1 and P5 data also clearly underlined the scale and rapid progression of pathological changes that occur in the neuromuscular system in this severe model of SMA.
Utilisation of GO-Elite MAPPFinder software to further investigate the potential function of genes shown to have modified expression levels identified 35 different cellular pathways which were modified in late-symptomatic (P5) Smn-/-;SMN2 spinal cord (Table 4) . This in silico analysis highlighted changes in pathways relating to extracellular matrix integrity and growth factor signalling in SMA pathology.
To validate the microarray findings and confirm that changes detected at the mRNA level in spinal cord led to corresponding changes at the protein level, we quantified protein expression levels of myelin protein zero (P0) in the spinal cord of late-symptomatic Smn-/-;SMN2 mice and wild-type littermates at P5 using fluorescent western blotting (see methods).
We observed a significant (~50%) reduction in P0 protein levels in Smn-/-;SMN2 mice, thereby validating the microarray dataset and confirming that the large reduction in P0 mRNA detected on the microarray resulted in corresponding reductions in protein expression (Figure 8 ).
Discussion
This study has generated two important findings. First, we have demonstrated that reduced Smn expression does not significantly modify pre-symptomatic lower motor neuron connectivity or gene expression in the spinal cord in vivo. Abnormal pre-symptomatic development of lower motor neuron connectivity is therefore unlikely to be a pre-requisite for subsequent pathology to occur in a mouse model of severe SMA. Second, we have shown that gene expression changes correlating with SMA pathology progress rapidly following the onset of symptoms, and that extracellular matrix integrity, growth factor signalling and/or myelination pathways may constitute viable therapeutic targets for stabilising lower motor neuron and spinal cord pathology in SMA. This study therefore highlights the importance of focusing on the role of Smn protein in maintaining the neuromuscular system once formed, rather than its role in regulating motor neuron outgrowth and axonogenesis, for understanding SMA pathogenesis.
Our data suggest that the developmental effects of reduced Smn levels reported in vitro as well as in zebra fish and Xenopus models in vivo [10] [11] [12] [13] [14] are not mirrored in mammalian SMA models in vivo. Whilst it remains possible that Smn protein can influence developmental pathways including axon outgrowth and pathfinding in mammals under some experimental conditions, our data demonstrate that such changes are not sufficient to cause defects in the development of lower motor neuron connectivity in mouse models in vivo and are therefore not likely to be a major contributing factor to SMA pathogenesis in human patients. As a result, efforts to understand the role of Smn protein in the triggering and progression of SMA pathology would likely be better served by focussing on events occurring during and around the onset of symptoms and motor neuron breakdown. Our data also suggest that modifier genes which influence disease severity in SMA, such as plastin 3
[25], are more likely to work through stabilising the neuromuscular system (e.g. by modifying actin dynamics) rather than by influencing pre-symptomatic developmental pathways such as axonogenesis [c.f. 25].
Although we could not detect alterations in pre-symptomatic development of lower motor neuron connectivity in vivo, we did observe some subtle differences between neuromuscular development of the rostral and caudal bands of the LAL, and between the AS and AAL muscles. The finding that endplate maturation was occurring faster in the caudal band of the LAL muscle is in agreement with our previous findings that motor units in this muscle band belong to the developmentally more advanced fast-synapsing ('FaSyn') subtype [7, 24] .
Whilst this may indicate that increased maturation is linked to increased vulnerability, advanced endplate maturation was also seen in the relatively non-vulnerable AAL muscle compared to the less mature endplates in the vulnerable AS muscle. These results indicate that the rate of endplate maturation is unlikely to directly impact upon motor unit vulnerability in SMA. This is in contrast to recent published findings suggesting that increasing endplate maturation by exercise stabilises the neuromuscular junction and confers neuroprotection [22] . In light of our findings we would suggest revising the conclusions of Biondi and colleagues [22] to state that, while exercise can clearly be neuroprotective in SMA, endplate maturation is probably a by-product of the exercise regime and is not likely to have a direct effect on lower motor neuron vulnerability.
One remarkable finding of the current study was that pre-symptomatic analyses of lower motor neuron morphology and gene expression revealed no detectable abnormalities in presymptomatic development of lower motor neuron connectivity at P1, in a severe mouse model of SMA where the disease kills the animals by P6-P7. This highlights the rapid progression of neuromuscular breakdown that occurs as a result of reduced SMN expression, but also gives great encouragement for the development of post-natally delivered treatments for SMA in human patients. Had we found evidence for widespread disruption of presymptomatic development of lower motor neurons, leading to subsequent changes in neuronal vulnerability, it would be difficult to envisage how this could be fully remedied by post-natal treatment options alone. By contrast, our results suggest the potential existence of a pre-symptomatic "therapeutic time window" in which the majority of lower motor neurons and neuromuscular synaptic connections remain phenotypicaly intact, extending into postnatal days even in a mouse model of severe SMA where death occurs by P5-P6. This work therefore provides encouragement for current efforts to treat SMA post-natally, using strategies such as increasing SMN levels in the nervous system [16, 26] [38] . It is conceivable that therapeutic strategies designed to preserve and support the extracellular matrix (often referred to as peri-neuronal nets in the nervous system) may help to sustain lower motor neuron form and function by influencing factors such as the maintenance of cellular relationships and adhesion, the control of synaptic plasticity and neurotransmitter receptor localisation, and the concentration of growth factors around neurons [39, 40] . Similarly, the finding that genes associated with growth factor signalling are dys-regulated in late-symptomatic SMA spinal cord suggests that lower motor neurons may be breaking down as a result of abnormal trophic signalling. Trophic factors have long been considered as potential therapeutic agents for SMA [41] , but a comprehensive analysis of the effects of different growth factors on SMA pathology has yet to be undertaken. Finally, our finding that key myelin proteins have reduced mRNA and protein levels in late-symptomatic SMA spinal cord may be of particular interest given that developmental downregulation of SMN in vivo coincides with the onset of myelination [42] . Further investigations into the importance of growth factors, the extracellular matrix and myelination in SMA pathogenesis are therefore required.
In summary, we have shown that abnormal pre-symptomatic development of lower motor neuron connectivity is not a pre-requisite for subsequent neuromuscular pathology in a mouse model of severe SMA. Future experiments examining neurodevelopmental aspects of the neuromuscular system in human tissue samples will now be required to confirm the relevance of our findings for human SMA pathogenesis. Future experiments will also be required to identify molecular mechanisms underlying the triggering of neuromuscular breakdown around the time of initial symptom onset, building on our identification of changes in pathways including extracellular matrix integrity, growth factor signalling and myelination. facilities in Oxford. Breeding and genotyping of these mice was performed as previously described [7] . Littermate mice (Smn +/+ ;SMN2) were used for controls throughout.
Materials & Methods
Mice
Immunocytochemistry
Neonatal (P1 for pre-symptomatic and P5 for late-symptomatic) Smn-/-;SMN2 mice and 
Imaging and analysis
Muscle preparations were viewed using either a standard epi-fluorescence microscope equipped with a chilled CCD camera (40x objective; 0.8NA; Nikon IX71 microscope;
Hammamatsu C4742-95), and/or a laser scanning confocal microscope (63x objective;
1.4NA; Zeiss Axioskop). TRITC-α-BTX-labelled preparations were imaged using 543nm excitation and 590nm emission optics and FITC-labelled preparations utilised 488nm excitation and 520nm emission optics. For confocal microscopy, 488nm and 543nm laser lines were used for excitation and confocal Z-series were merged using ImageJ software. For deconvolution analysis, images were acquired using nyquist sampling and deconvolved using Huygens deconvolution software. All images were assembled for publication using Adobe Photoshop software.
Morphological Quantification and Statistics
All muscles used for quantification were imaged and reconstructed using Adobe Photoshop software so that the whole innervation pattern could be visualised, thus allowing orientation for subsequent analysis and elimination of any muscles which were damaged during dissection. All analyses were performed with the experimenter blind to genotype and muscle region. The number of endplates per axon was quantified by evaluating axon number from deconvolved images. Images were taken at approximately 100µm from the endplate area of interest to minimise variability introduced from axon branching occurring adjacent to sites of innervation. All muscles in which the complete area of innervation could not be seen, or additional axons branches were present, were excluded from further analysis. Axon numbers were counted by visualisation in the X-Y plane and scanning up and down through the zseries. This was done at three pre-defined points per image with images re-blinded between each measurement. The average of each three counts was divided by the total number of endplates innervated by the axon bundle to give the average number of axons per endplate.
The average number of inputs was evaluated by counting the number of pre-synaptic inputs contacting a given endplate. Any endplate in which the complexity of innervation made it difficult to define (e.g. overlying a major nerve branch) was excluded from further analysis.
Quantification was performed on a minimum of 3 images per muscle (AS,AAL) or muscle band (LAL) totalling a minimum of 15 endplates per muscle/muscle band per mouse. To quantify sprouting, sprouts were catagorised as 'small sprouts' (those less than 150µm) or 'super sprouts' (those exceeding 150µm). Sprouts were defined as a neurofilament positive process that did not project to a cluster of AChR receptors. Small sprouts were quantified by counting the number of sprouts in a given field of view expressed in relation to the number of endplates present. A minimum of three fields of view were evaluated for each muscle (AAL/AS) or muscle band (LAL). Super sprouts were quantified by counting the total number of sprouts in a muscle region (C2 or R3-5 for LAL, whole muscle for AS/AAL) divided by the total number of endplates in the relevant region. Endplate maturation was evaluated by catagorising endplates as either uniform (even distribution of AChRs), folded (bright bands within the AChR region) or perforated (holes within the AChR staining) (see Figure 5 ). Any endplate which was difficult to quantify due to orientation or proximity of other endplates was excluded from further analysis. For endplate area measurements, confocal images were imported into image J software and their outline was manually traced and the software used to calculate the area. Again, any endplate which difficult to measure due to orientation or proximity of other endplates was excluded. All data were collected and analysed using GraphPad Prism software.
RNA Isolation and Microarray
Whole spinal cords were removed and RNA was extracted using an RNEasy micro kit (Qiagen). Any genomic DNA was removed using an on column digest. The quality and integrity of RNA was assessed on a BioAnalyzer; all samples had a RNA Integrity Number 
Quantitative fluorescent western blotting
Quantitative western blots were performed as described previously 
